BCN Biosciences
Early-stage biotechnology company focused on oncology drug discovery and preclinical development of small-molecule and biologic therapeutic candidates. Research emphasis includes endothelial-derived gene targets, monoclonal antibody development, phenotypic small-molecule screening, and early-stage cancer detection technologies. Engages in academic collaborations for radiomitigation small-molecule discovery.
Industries
Nr. of Employees
small (1-50)
BCN Biosciences
Patents
Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using compound 512
US-11534437-B2
View DetailsMethods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using YEL002/BCN057
US-11364231-B2
View Details
Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using compound 512
US-11534437-B2
View DetailsMethods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using YEL002/BCN057
US-11364231-B2
View DetailsProducts
Monoclonal antibody pipeline (lead candidate in definitive preclinical studies)
Pipeline of monoclonal antibody therapeutics directed against endothelial-derived gene targets; a lead antibody candidate is being advanced through definitive preclinical studies for oncology indications.
Small-molecule radiomitigation lead series
Small-molecule lead series discovered in collaboration with an academic radioprotector center for protecting normal tissues from radiation damage; identified through phenotypic screening and evaluated in animal survival models.
Monoclonal antibody pipeline (lead candidate in definitive preclinical studies)
Pipeline of monoclonal antibody therapeutics directed against endothelial-derived gene targets; a lead antibody candidate is being advanced through definitive preclinical studies for oncology indications.
Small-molecule radiomitigation lead series
Small-molecule lead series discovered in collaboration with an academic radioprotector center for protecting normal tissues from radiation damage; identified through phenotypic screening and evaluated in animal survival models.
Services
Collaborative R&D engagements with academic institutions and industry partners for discovery and preclinical development of therapeutics.
Collaborative R&D engagements with academic institutions and industry partners for discovery and preclinical development of therapeutics.
Expertise Areas
- Oncology drug discovery
- Monoclonal antibody development
- Small-molecule lead discovery
- Target identification for endothelial-derived genes
Key Technologies
- Monoclonal antibody generation
- Phenotypic small-molecule screening
- Cellular clonogenic assays
- DNA damage assays